• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Exact Sciences

Exact Sciences

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. UPDATE: Market bears resurface, S&P 500 balks -2-

    UPDATE: Market bears resurface, S&P 500 balks -2-

  2. UPDATE: Market bears resurface, S&P 500 balks at the breakdown point

    UPDATE: Market bears resurface, S&P 500 balks at the breakdown point

  3. Emerging Molecular Diagnostic Technologies and Strategic Profiles of Leading Suppliers 2017 - Research and Markets

    Emerging Molecular Diagnostic Technologies and Strategic Profiles of Leading Suppliers 2017 - Research and Markets

  4. Bull trend intact, S&P 500 survives second -2-

    Bull trend intact, S&P 500 survives second -2-

  5. Bull trend intact, S&P 500 survives second test of 50-day average

    Bull trend intact, S&P 500 survives second test of 50-day average

  6. Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023: Focus on Biomarker Test Type, Application & Market Trends - Research and Markets

    Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2017-2023: Focus on Biomarker Test Type, Application & Market Trends - Research and Markets

  7. UPDATE: S&P 500 survives test of 50-day -2-

    UPDATE: S&P 500 survives test of 50-day -2-

  8. UPDATE: S&P 500 survives test of 50-day average amid technical cross currents

    UPDATE: S&P 500 survives test of 50-day average amid technical cross currents

  9. Morningstar Rating for Stocks Performance Update

    With the first half of 2005 in the rearview mirror, it's time for another review of how the stock star rating is doing. I'm happy to report that after lagging a bit in the first quarter, we've now pulled ahead of most of our benchmarks. The First Half of 2005 As a reminder, we measure our ...

  10. How the Stock Star Rating Is Performing

    With 2004 in the rearview mirror, I thought I'd share another Morningstar Rating for stocks performance review with you. Our results continue to be positive, which makes this a pleasant review to write. As before, we're measuring ourselves by creating a hypothetical portfolio that buys 5-star ...

12

©2017 Morningstar Advisor. All right reserved.